Ovarian cancer and gonadotropins in Vitro: New evidence in favor of independence

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 4289-4295

  Ala Fossi, Sirkka Liisa ^b   Grenman, Seija ^b   Zhang, F U Ping ^b   Bläuer, Merja ^b   Punnonen, Reijo ^b   Mäenpää, Juhani ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b NONE

Author keywords

Cultured ovarian carcinoma cells; FSH; hCG; Inhibins

Indexed keywords

CA 125 ANTIGEN; CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; INHIBIN; INHIBIN A; PROGESTERONE; TESTOSTERONE;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL PROLIFERATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CA-125 ANTIGEN; CELL DIVISION; CHORIONIC GONADOTROPIN; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPINS; HUMANS; INHIBINS; OVARIAN NEOPLASMS; RECEPTORS, GONADOTROPIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0032763987     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Vale W, Rivier C, Hsueh A, et al: Chemical and biological characterization of the inhibin family of protein hormones. Recent Progress in Hormone Research 44: 1-34, 1988.
2. Burger HG, Fuller PJ: The inhibin/activin family and ovarian cancer. Trends Endocrinol Metab 7: 197-202, 1996.
3. Findlay JK: An update on the roles of inhibin, activin and follistatin as local regulators of folliculogenesis. Biol Reprod 48: 15-23, 1993.
4. B-subunit messenger ribonucleic acid levels in cultured human granulosa-luteal cells. Fertil Steril 65: 954-960, 1996.
5. Groome NP, Illingworth PJ, O'Brien, et al: Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 81: 1401-1405, 1996.
6. Halvorson L, DeCherney AH: Inhibin, activin and follistatin in reproductive medicine. Fertil Steril 65: 459-469, 1996.
7. Radisavljevic SV: The pathogenesis of ovarian inclusion cysts and cystomas. Obstet Gynecol 49: 424-429, 1977.
8. Fathalla MF: Incessant ovulation - A factor in ovarian neoplasia ? Lancet 2: 163, 1971.
9. Massague J: The transforming growth factor beta family. Ann Rev Cell Biol 6: 597-641, 1990.
10. Wallace EM: Inhibins: New tumour markers in gynaecology. Tumor marker update 8: 105-110, 1996.
11. Zheng W, Luo MP, Welt C, et al: Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol 69: 23-31, 1998.
12. Lappöhn R, Burger H, Bouma J, Bangah M Krans M, de Bruijin: Inhibin as a marker for granulosa cell tumors. N Engl J Med 321: 790-793, 1989.
13. Jobling T, Mamers P, Healy DL, et al: A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol 55: 285-289, 1994.
14. Cooke I, O'Brien M, Charnock FM, Groome N, Ganesan TS: Inhibin as a marker for ovarian cancer. Br J Cancer 71: 1046-1050, 1995.
15. Healy DL, Burger HG, Mamers P, et al: Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 329: 1539-1542, 1993.
16. Healy DL, Mamers P, Bangah M, Burger HG: Clinical and pathophysiological aspects of inhibin. Human Reprod 8: 138-140, 1993.
17. Burger HG: Inhihin as a tumour marker. Clinical Endocrinology 41: 151-153, 1994.
18. Lambert-Messerlian GM, Steinhoff M, Zheng W, et al: Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer. Gynecologic Oncology 65: 512-516, 1997.
19. Grenman S, Engblom P, Rantanen V, Klemi P, Isola J: Cytogenetic characterization of five new ovarian carcinoma cell lines. Abstract. Acta Obstet Gynecol Scand. Supplement 176: 44, 1997.
20. Engblom P, Rantanen V, Kulmala J, Helenius H, Grenman S: Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. Br J Cancer 79: 286-292, 1999.
21. Wimalasena J, Meehan D, Cavallo C: Human epithelial ovarian cancer cell steroid secretion and its control by gonadotropins. Gynecol Oncol 41: 56-63, 1991.
22. Jia XC, Oikawa M, Bo M, et al: Expression of human luteinizing hormone (LH) receptor: interaction with LH and chorionic gonadotropin from human but not equine, rat, and ovine species. Mol Endocrinol 5: 759-768, 1991.
23. Minegishi T, Nakamura K, Takakura Y, et al: Cloning and sequencing of human FSH receptor cDNA. Biochem Biophys Res Commun 175: 1245-1130, 1991.
24. Zhang F-P, Rannikko AS, Manna PR, Fraser HM, Huhtaniemi IT: Cloning and functional expression of the luteinizing hormone receptor complementary deoxyribonucleic acid from the marmoset monkey testis: absence of sequences encoding exon 10 in other species. Endocrinology 138: 2481-2490, 1997.
25. Ala-Fossi S-L, Mäenpää J, Bläuer M, Aine R, Tuohimaa P, Punnonen R: Inhibin A and B in peri- and postmenopause. Maturitas 30: 273-281, 1998.
26. Klein NA, Illingworth PJ, Groome NP, McNeilly AS, Battaglia, Soules MR: Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and tollicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab 81: 2742-2745, 1996.
27. Burger HG, Cahir N, Robertson DM, et al: Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. Clinical Endocrinology 48: 809-813, 1998.
28. DiSimone N, Crowley WF, Wang O, Sluss PM, Schneyer AL: Characterization of inhibin/activin subunit, follistatin and activin type II receptors in human ovarian cancer cell lines: A potential role in autocrine growth regulation. Endocrinology 137: 486-494, 1996.
29. Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF, Schneyer AL: Presence of activin, inhibin and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab 82: 3720-3727, 1997.
30. Pelkey TJ, Frierson HF Jr., Mills SE, Stoler MH: The diagnostic utility of inhibin staining in ovarian neoplasms. Int J Gynecol Pathol 17: 97-105, 1998.
31. Arora DS, Cooke IE, Ganesan TS, et al: Immunohistochemical expression of inhibin/activin subunits in epithelial and granulosa cell tumours of the ovary. J Pathol 181: 413-418, 1997.
32. Gurusinghe CJ, Healy DL, Jobling T, Mamers P, Burger HG: Inhibin and activin are demonstrable by immunohistochemistry in ovarian tumor tissue. Gynecol Oncol 57: 27-32, 1995.
33. Groome NP, Illingworth PJ, O'Brien M, Priddle J, Weaver K, McNeilly AS: Quantification of inhibin pro-αC containing forms in human serum by a new ultrasensitive two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 80: 2926-2932, 1995.
34. Heinonen PK, Mörsky P, Aine R, Koivula T, Pystynen P: Hormonal activity of ovarian tumours in postmenopausal women. Maturitas 9: 325-338, 1988.
35. Aiman J, Forney JP, Parker R: Secretion of androgens and estrogens by normal and neoplastic ovaries in postmenopausal women. Obstetrics and Gynecology 68: 1-5, 1986.
36. Poels LG, Jap PH, Raemakers FC, et al: Characterization of a hormone producing ovarian carcinoma cell line. Gynecol Oncol 32: 203-214, 1989.
37. van Niekerk CC, Poels LG, Jap PHK, et al: Characterization of a human ovarian carcinoma cell line, OTN 14, derived from a mucinous cystadenocarcinoma. Int J Cancer 42: 104-111, 1988.
38. Zheng W, Magid MS, Kramer EE, Chen Yao-Tseng: Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol 148: 47-53, 1946.
39. Rajaniemi H, Kauppila A, Rönnberg L, Selander K, Pystynen P: LH (hCG) receptor in benign and malignant tumors of human ovary. Acta Obstet Gynecol Scand Suppl 101: 83-86, 1981.
40. Stouffer RL, Grodin MS, Davis JR, Surwit EA: Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotropin in human ovarian cancers. J Clin Endocrinol Metab 59: 441-446, 1984.
41. Nakano R, Kitayama S, Yamoto M, Shima K, Ooshima A: Localization of gonadotropin binding sites in human ovarian neoplasms. Am J Obstet Gynecol 161: 905-910, 1989.
42. Wimalasena J, Dostal R, Meehan D: Gonadotropins, estradiol and growth factors regulate epithelial ovarian cancer cell growth. Gynecol Oncol 46: 345-350, 1992.
43. Simon WE, Albrecht M, Hänsel M, Dietel M, Hölzel F: Cell lines derived from human ovarian carcinomas: Growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 70: 839-845, 1983.
44. Thompson MA, Adelson MD, Kaufmann LM: Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium. J Clin Endocrinol Metah 72: 1036-1041, 1991.
45. Kurbacher CM, Jäger W, Kurbacher JA, Bittl A, Wildt L, Lang N: Influence of human luteinizing hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumor Biol 16: 374-384, 1995.
46. Kabawat SE, Bast RCJ, Welch WR, Knapp RC, Colvin RN: Tissue distribution of a coelomic epithelium -related antigen recognized by the monoclonal antibody OC 125. Int J Gynecol Pathol 2: 275-285, 1983.
47. Berek JS, Bast RC: Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 76: 2092-2096, 1945.
48. Möbus V, Gerharz CD, Press U, et al: Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int J Cancer 52: 76-84, 1992.